Author:
Nikolaeva E. Yu.,Zhelayeva Y. R.,Susova O. Yu.,Mitrofanov A. A.,Varachev V. O.,Nasedkina T. V.,Zverev V. V.,Svitich O. A.,Ammour Y. I.
Reference23 articles.
1. Nikolaeva E.Yu., Shchetinina Yu.R., Shokhin I.E., Zverev V.V., Svitich O.A., Susova O.Yu., Mitrofanov A.A., Ammour Yu.I. 2022. Measles virus as a vector platform for glioblastoma immunotherapy (review). Razrab. Regist. Lek. Sredstv. 11, 51‒58.
2. Stupp R., Mason W.P., Van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E., Mirimanoff R.O.; European organization for research and treatment of cancer brain tumor and radiotherapy groups; National Cancer Institute of Canada clinical trials group. 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.
352, 987–996.
3. Stupp R., Hegi M.E., Mason W.P., Van den Bent M.J., Taphoorn M.J., Janzer R.C., Ludwin S.K., Allgeier A., Fisher B., Belanger K., Hau P., Brandes A.A., Gijtenbeek J., Marosi C., Vecht C.J., Mokhtari K., Wesseling P., Villa S., Eisenhauer E., Gorlia T., Weller M., Lacombe D., Cairncross J.G., Mirimanoff R.O.; European organisation for research and treatment of cancer brain tumour and radiation oncology groups; National Cancer Institute of Canada clinical trials group. 2009. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EO-RTC-NCIC trial. Lancet Oncol.
10, 459–466.
4. Taylor O.G., Brzozowski J.S., Skelding K.A. 2019. Glioblastoma multiforme: An overview of emerging therapeutic targets. Front. Oncol.
9, 963.
5. Suryawanshi Y.R., Schulze A.J. 2021. Oncolytic viruses for malignant glioma: On the verge of success? Viruses.
13, 1294.